KRAS and hepatocellular carcinoma: In hepatocellular carcinoma, NRAS expression is markedly upregulated in hepatocellular carcinoma tissues and cell lines; the combined inhibition of KRAS and NRAS reduces the resistance of hepatocellular carcinoma to sorafenib.19